KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Nektar Therapeutics (NKTR) Leases (2016 - 2025)

Nektar Therapeutics has reported Leases over the past 12 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Leases at $2.9 million for Q4 2025, down 65.04% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 65.04% YoY), and the annual figure for FY2025 was $2.9 million, down 65.04%.
  • Leases for Q4 2025 was $2.9 million at Nektar Therapeutics, down from $7.2 million in the prior quarter.
  • Over the last five years, Leases for NKTR hit a ceiling of $125.0 million in Q1 2021 and a floor of $2.9 million in Q4 2025.
  • Median Leases over the past 5 years was $23.9 million (2023), compared with a mean of $48.2 million.
  • Biggest five-year swings in Leases: fell 6.67% in 2021 and later tumbled 71.55% in 2023.
  • Nektar Therapeutics' Leases stood at $117.0 million in 2021, then tumbled by 54.34% to $53.4 million in 2022, then tumbled by 66.3% to $18.0 million in 2023, then plummeted by 53.28% to $8.4 million in 2024, then tumbled by 65.04% to $2.9 million in 2025.
  • The last three reported values for Leases were $2.9 million (Q4 2025), $7.2 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.